Kinnate Biopharma KNTE

$ 2.65 0.0%

Annual report 2023
added 03-28-2024

Kinnate Biopharma Balance Sheet 2011-2024 | KNTE

Annual Balance Sheet Kinnate Biopharma

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-53.8 M	-25.1 M	-	-365 M	-76.5 M	-7 M	-	-	-	-	-	-	-
Long Term Debt	2.28 M	3.19 M	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	892 K	991 K	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	93.1 M	-	-	-	-	-	-	-	-
Total Current Liabilities	12 M	17.2 M	12.4 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	14.3 M	20.4 M	12.4 M	7.3 M	95.1 M	467 K	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-372 M	-259 M	-143 M	-53.3 M	-17.6 M	-7.63 M	-	-	-	-	-	-	-
Total Assets	174 M	279 M	367 M	401 M	77.6 M	8.08 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	57 M	29.3 M	116 M	365 M	-	-	-	-	-	-	-	-	-
Book Value	159 M	258 M	354 M	393 M	-17.5 M	7.61 M	-	-	-	-	-	-	-
Total Shareholders Equity	159 M	223 M	319 M	393 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Kinnate Biopharma

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	2.52 M	2.74 M	2.96 M	3.19 M	3.45 M	3.7 M	4.14 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	18.3 M	18.5 M	21.1 M	20.4 M	18.8 M	15.2 M	17.8 M	12.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-355 M	-324 M	-292 M	-259 M	-228 M	-197 M	-170 M	-143 M	-117 M	-92.2 M	-70.8 M	-53.3 M	-53.3 M	-53.3 M	-53.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	191 M	216 M	244 M	279 M	302 M	324 M	349 M	367 M	386 M	405 M	386 M	401 M	401 M	401 M	401 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	51.7 M	34.5 M	73.6 M	29.3 M	61.3 M	64.9 M	64.5 M	116 M	170 M	168 M	182 M	365 M	365 M	365 M	365 M	76.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	172 M	198 M	223 M	258 M	283 M	309 M	331 M	354 M	386 M	405 M	386 M	401 M	401 M	401 M	401 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	172 M	198 M	223 M	223 M	248 M	274 M	296 M	319 M	341 M	361 M	379 M	393 M	393 M	393 M	393 M	-17.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency